Protocol Ledger

NCT05722886 · Phase II/III · RECRUITING

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Interventional Phase II/III clinical trial protocol NCT05722886 sponsored by Cancer Research UK in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-03-01 Enrollment: 825 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05722886
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)825 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05722886
Protocol FieldVerified Registry Value
NCT IdentifierNCT05722886
Consolidated Lead SponsorCancer Research UK
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment825 participants (ESTIMATED)
Registered Start Date2023-03-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05722886
Hospital Research SiteLocationSite Profile
Addenbrooke's HospitalCambridge, United KingdomOpen Hospital Dossier ->
Western General HospitalEdinburgh, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI